If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Oncology - General
Sub-Investigator(s):
Sponsors: Internal
Details (Indentifier #): NCT05694338
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Gilead Sciences
Details (Indentifier #): NCT05633654
Title: A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT04457596
Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: NCI
Details (Indentifier #): NCT04340141
Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT03793166
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT02194738
Title: A221805: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT04137107
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
Details (Indentifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sponsors: Astra Zeneca
Details (Indentifier #): NCT04964934
Title: EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT04092283
Showing 1-10 of 27 Results